Peptide record

TPDB13092

Antibacterial Antiviral Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13092
Antibacterial Antiviral Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia AI4AVP dbAMP 3.0 PD_Hemolysis
standard
No
A 18-aa standard-residue multi-activity (Antibacterial, Antiviral, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AI4AVP, and other sources, with an available 3D structural model.
Sequence
FLFSLIRKAIGGLISAFK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C97H157N23O21
NDCEQHMPTWYV
ILF
1981.45
11.64
3
0
11
+3
-0.62
1.233
141.11
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
3
I
3
L
2
K
0
M
3
F
0
P
2
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 3 L: 3 K: 2 M: 0 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
18 reviewed residue count
C97H157N23O21 sequence-only estimate (linear, free termini)
1981.45 sequence-only estimate (linear, free termini)
11.64 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
-0.62 sequence-only estimate (linear, free termini)
1.233 sequence-only estimate (linear, free termini)
Evidence Records 21 records
Evidence 1 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

A. baumannii ATCC 19606

Source & Reference

NA

Other

active against E.coli ATCC 25922 (MIC> 256 ug/ml), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.
Evidence 2 Activity

Activity

MIC
Antibacterial
>256 µg/mL

Target

E.cloacae ATCC 700323

Source & Reference

NA

Other

l), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 3 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

Staphylococcus aureus MSSA ATCC 25923

Source & Reference

NA

Other

g/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 4 Activity

Activity

MIC
Antiviral
32 µg/mL

Target

A. baumannii ATCC 19606

Source & Reference

dbAMP 3.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
active against E.coli ATCC 25922 (MIC> 256 ug/ml), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.
Evidence 5 Activity

Activity

MIC
Antiviral
>256 µg/mL

Target

E.cloacae ATCC 700323

Source & Reference

dbAMP 3.0

Other

l), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 6 Activity

Activity

MIC
Antiviral
8 µg/mL

Target

Staphylococcus aureus MSSA ATCC 25923

Source & Reference

dbAMP 3.0

Other

g/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 7 Activity

Activity

IC50
Toxicity
33.2 µM
Cytotoxic
IC50 | 33.2 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 8 Activity

Activity

IC50
Toxicity
26.1 µM
Cytotoxic
IC50 | 26.1 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 9 Activity

Activity

49.4% Hemolysis
Toxicity
80 µM
Hemolytic Cytotoxic
49.4% Hemolysis | 80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 10 Activity

Activity

47.9% Hemolysis
Toxicity
60 µM
Hemolytic Cytotoxic
47.9% Hemolysis | 60 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 11 Activity

Activity

36.1% Hemolysis
Toxicity
40 µM
Hemolytic Cytotoxic
36.1% Hemolysis | 40 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 12 Activity

Activity

16.8% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
16.8% Hemolysis | 20 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 13 Activity

Activity

5.1% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
5.1% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 14 Activity

Activity

0% Hemolysis
Toxicity
1-5 µM
Hemolytic Cytotoxic
0% Hemolysis | 1-5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 15 Activity

Activity

10% Hemolysis
Toxicity
9 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 9 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 16 Activity

Activity

50% Hemolysis
Toxicity
54 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 54 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 17 Activity

Activity

LC
Toxicity
256 µg/mL
Cytotoxic
LC | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 18 Activity

Activity

LC50
Toxicity
113.8 µg/mL
Cytotoxic
LC50 | 113.8 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 19 Activity

Activity

10% Hemolysis
Toxicity
24 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 24 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 20 Activity

Activity

50% Hemolysis
Toxicity
78 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 78 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 21 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis